Facial basal cell carcinomaBMJ 2012; 345 doi: http://dx.doi.org/10.1136/bmj.e5342 (Published 21 August 2012) Cite this as: BMJ 2012;345:e5342
- Julia M Baxter, specialty registrar in ophthalmology,
- Anand N Patel, specialty registrar in dermatology,
- Sandeep Varma, consultant dermatologist and dermatological surgeon
- Correspondence to: S Varma
- Accepted 1 August 2012
Basal cell carcinoma (BCC) is a the most common human cancer and its incidence is increasing
Most BCCs occur on the head and neck and are easily recognised and treated
With timely recognition and treatment the outlook is usually excellent
Many different treatment options are available
Difficult to treat areas require specialist intervention
The cost to the NHS of treating BCC and other non-melanoma skin cancers is high
Basal cell carcinoma (BCC) is a locally invasive cancer of epidermal basaloid cells. It is the most common cancer in humans,1 and its incidence will soon surpass that of all other cancers.2 Skin cancers are categorised into two groups—melanomas and non-melanoma skin cancers. Of the non-melanoma skin cancers, 75-80% are BCCs3 4 5 and up to 85% of these are on the head and neck.4 5 6 7 8 9 10 11 12 13 14 15 16 The remainder are predominately squamous cell carcinomas. Delay in presentation is associated with increased tumour growth.17 Timely recognition is important because early identification can limit the extent of facial tissue involvement and subsequent resection, thereby resulting in a better cosmetic and functional reconstruction. Evidence suggests that denial is the main reason for delay in presentation with non-melanoma skin cancer.17
This review focuses on the diagnosis, investigation, and management of BCC of the head and neck.
Sources and selection criteria
We searched PubMed using keywords “basal cell carcinoma”, “facial basal cell carcinoma”, “facial non-melanoma skin cancer”, “head and neck basal cell carcinoma”, and “head and neck non-melanoma skin cancer”. We targeted more recent studies and review articles. We also consulted National Institute for Health and Clinical Excellence guidelines and other national guidance.
Who gets BCC?
The incidence of BCC varies geographically (table⇓) and is increasing worldwide.10 11 12 13 14 15 18 19 20 21 22 In the United States procedures performed for non-melanoma skin cancer at all sites almost doubled from 1994 to 2006.23 The lifetime risk has been estimated at more than 30% in a white German population,24 28-33% in the US,25 and 15-28% for women and 17-39% for men in Canada.6 In Australia the lifetime incidence of BCC is now greater than 50% (C Del Mar, personal communication, 2012). About 75 000 new cases of BCC occur each year in the United Kingdom, and the incidence is predicted to rise up to the year 2040. Because of the lack of non-melanoma skin cancer registries, the incidence is probably underestimated.26 27
The greatest risk factor for the development of BCC is exposure to ultraviolet radiation.24 This explains geographical variance and why disease is more common in areas of the body exposed to the sun. Sun exposure in childhood is especially important.24 BCC is usually diagnosed after 40 years of age and is slightly more common in men,3 6 22 28 29 30 31 32 with some studies showing that the disease is more aggressive in men than in women.33 34 With increasing age, the proportion of BCCs that occur on the head and neck increase.7 People with skin types that burn easily and tan poorly have 10-20-fold higher rates of BCC than those with dark skin, even when living in the same area.31 BCC is far less common in children,w1 and less than 2% of BCCs occur in pigmented skin because of the photoprotection provided by melanin.w2 Other risk factors include radiotherapy, arsenic, and immunosuppression,4 especially in organ transplant recipients, who have a 10-fold higher incidence of this cancer.w3 w4 BCCs may develop on the face at sites of traumaw5-w7 and in sebaceous naevi.w8 A long term follow-up study suggests that exposure to even high doses of PUVA (psoralen and ultraviolet A radiation) does not greatly increase the risk of BCC.w9
Genetic conditions that predispose to the development of multiple BCCs—such as naevoid basal cell carcinoma (Gorlin) syndrome, xeroderma pigmentosum, albinism, and Bazex syndrome—are not discussed in this review.
How do BCCs present?
BCC was first described as a rodent ulcer in 1824,w10 and a spontaneous ulcer or an ulcer on the face that fails to heal should arouse suspicion. BCC has a variety of clinical presentations, but most patients describe a non-healing lump or “sore spot,” which grows slowly and is otherwise asymptomatic. The lesion may cycle through bleeding and crust formation, a scab may separate during sleep leaving blood on the pillow, or it may catch on clothing. On the basis of their clinical morphology, BCCs are classified into four main subtypes; nodular or nodulo-ulcerative, superficial, morphoeic, or infiltrative and pigmented. Different types of BCC occur at different anatomical locations and this influences treatment and prognosis.w11
Nodular BCC, which affects mainly the head and neck, is the most common type in the UK.3 7 9 24 32 w12 It presents as a pearly or translucent papule, plaque, nodule, or cyst-like lump, which has a rolled edge, telangiectasia, and central depression, with or without ulceration (box 1; fig 1A⇓)
Superficial BCC may present as a slowly growing scaly pink patch or plaque, which resembles eczema, psoriasis, or Bowen’s disease (intraepidermal carcinoma) (fig 1B)
Morphoeic BCC resembles a slowly enlarging whitish scar that can have extensive subclinical spread (fig 1C)
Some BCCs are pigmented and can look like melanoma (fig 1D).
Box 1 Classic features of nodular basal cell carcinoma
Pearly papule or nodule with central depression or umbilication
Raised rolled edge
May enlarge to a dome shaped tumour or ulcerate
How are BCCs diagnosed?
Most BCCs can easily be diagnosed on the basis of the history and clinical examination. In case of uncertainty, pathognomonic arborising telangiectasia detected using a hand held dermatoscope will confirm the diagnosis.2 32 w13 Other features on dermatoscopy include multiple blue-grey globules, maple leaf-like areas, blue-grey ovoid nests, and spoke wheel areas.w14 Several differential diagnoses exist (box 2), so obtain histological verification if there is any doubt. After diagnosis, the risk of a further BCC is about 10 times greater than in the general population.w15
Box 2 Differential diagnosis
Bowen’s disease (intraepidermal carcinoma)
Solar or actinic keratosis
Squamous cell carcinoma
Sebaceous gland hyperplasia (enlarged facial sebaceous glands)
Intradermal naevus (flesh coloured mole)
Malignant melanoma, including amelanotic melanoma
What does a BCC look like histologically?
Lesions usually grow slowly, sometimes by as little as 0.5 mm per 70 days.w16 Nodular BCC is characterised by large solid lobules of atypical basaloid cells that exhibit a peripheral palisade (fig 2⇓). BCCs infiltrate tissues in a three dimensional manner,w17 with asymmetrical subclinical finger-like ramifications; they tend to invade along tissue planes, the periosteum, and nerves.3 The pattern is sometimes described to patients as a tree trunk with spreading roots.
What is high risk BCC?
Most BCCs on the body are “low risk” tumours. However, those on the face exhibit a wider subclinical spread than at other sites.30 After adjusting for surface area, BCC is at least four times more common on embryonic fusion planes than on other regions of the midface.w18
Anatomical areas at high risk for invisible tumour spread and therefore incomplete treatment are the nose, ear, eyelid, eyebrow, and temple (known as the H-zonew19; fig 3⇓). Box 3 lists the features of “high risk” BCCs, which should be considered for specialist assessment and treatment by those who are experienced in the management of challenging facial skin cancers.4 The periocular area merits special attention because 90-95% of all malignant eyelid tumours are BCCs,w20 and 5-10% of all skin cancer occurs on the eyelid.w21 Periocular BCCs most commonly occur on the lower eyelid (43%), followed by medial canthus (26%), upper eyelid (12%), and lateral canthus (8%).w21 Careful examination is needed because 20-40% of periocular BCCs are clinically misdiagnosed.w22 w23 If left untreated, disease can spread to the globe, which will require exenteration. A screening tool for periocular BCCs in primary care (the LUI key) uses the three clinical features that most consistently predict a malignant process: loss of lashes, ulceration, and infiltration.w22 Orbital extension (usually along the periosteum) and intracranial spread of the tumour can be fatal.
Box 3 High risk basal cell carcinomas
Size >2 cm diameter
Location in high risk anatomical areas (centrofacial, periocular, “H zone,” and embryological fusion zones of face)
Poorly defined edges
Morphoeic, infiltrative, or aggressive histological subtypes
Perineural or perivascular invasion
Recurrent or previously incompletely excised basal cell carcinoma
Host factors (immunosuppression, especially if organ transplant recipient)
What are the treatment options for BCC?
The British Association of Dermatologists and the American Academy of Dermatology have issued guidelines for the management of BCC.19 w24 Treatment options include wide local excision, Mohs micrographic surgery, radiotherapy, photodynamic treatment, imiquimod, curettage and cautery, cryotherapy, and lasers. The choice of treatment is determined by tumour (site, size, subtype, primary, or recurrent lesion) and patient factors (age, comorbidities, preference). Different sites on the face are better suited to different treatment regimens.w25 Elderly patients or those with serious comorbidities and low risk tumours may be more suited to non-surgical treatments. In addition, local availability of services, experience, and geographical issues may play a role in the choice of treatment. For a small subset of infirm or elderly patients or those with serious comorbidities, it may be best not to start on treatment. Patients are often managed by a multidisciplinary team of dermatologists, plastic surgeons, general practitioners, ophthalmologists, pathologists, oncologists, radiologists, ear nose and throat specialists, maxillofacial surgeons, and specialist nurses. Recent guidance from the National Institute for Health and Clinical Excellence (NICE) has advocated several models of care based on lesion complexity and operator experience, with an emphasis on treating certain BCCs closer to patients’ communities.w26 Detailed and clear guidance is available on the provision of skin cancer services in terms of local multidisciplinary teams, specialist multidisciplinary teams, cancer networks, and the role of general practitioners with specialist interests.w26-w28
Wide local excision
Most facial BCCs can be treated successfully by standard surgical excision (also called wide local excision or excision with predetermined margins)w29 w30 under local anaesthesia in the outpatient department. Margins are determined by careful clinical examination or by biopsy. A 4 mm surgical margin for primary well defined BCC measuring less than 20 mm ensures a complete clearance of over 95%.w31 However, a margin of 3 mm, even for lesions that measure just 6×5 mm on average, will clear only about 85% of tumours.w32 w33 Aggressive subtypes, such as morphoeic BCC, can have extensive subclinical spread and require wider surgical margins to ensure complete clearance (fig 4⇓).w32 w34 Despite apparent histological clearance, recurrences can occur.w35 The cosmetic outcome from standard excisions depends on the experience of the surgeon and the site, size, and histology of the tumour.w36 In one study, results were better for untreated tumours than for incompletely excised tumours or tumours that recurred after surgery.w37 Recently, dermoscopy has helped guide surgery for facial BCC.w38
Mohs micrographic surgery
Frederic Mohs first described his micrographic surgical technique for treating skin cancer in 1941.w39 Later, in a consecutive series of 9716 BCCs, he reported a five year cure rate of 99.3%.w40 Currently, Mohs micrographic surgery is considered the gold standard for morphoeic, micronodular, and infiltrative facial BCCs and recurrent or incompletely excised BCCs at high risk sites (box 3).w25 w41-w43 The technique involves excising the cancer, drawing a map of the excised tissue, colour coding the margins, sectioning the fresh frozen tissue horizontally, and examining all of the surgical margin while the patient waits.w44 w45 Further excision is carried out only when tumour is detected microscopically at the surgical margin. This is why Mohs surgery has the highest cure rates for skin cancer and spares normal tissue, thereby allowing more reconstructive options, an important functional and aesthetic consideration for the face. Sites such as the periocular, perioral, and perinasal areas have high functional and cosmetic importance. Several papers show that for periocular tumours Mohs surgery allows important anatomical structures to be preserved.w46 w47 Cure rates are 98-99% for primary facial BCC and 96% for recurrent BCC.w41 w48 Because standard excisional surgery has a higher incomplete excision rate for facial BCC, especially those located on the central face, Mohs surgery is the treatment of choice for these, for all high risk BCCs, and for recurrent lesions.w46 w47 w49 A risk scale can help decisions on treatment.w50 Attempts to calculate the cost effectiveness of Mohs surgery when compared with standard excisional surgery have resulted in different opinions.w43 w51-w53
Radiotherapy includes superficial radiography, brachytherapy, and electron beam radiotherapy.w54 Radiotherapy is mainly effective for primary BCC and sometimes for recurrent or incompletely excised BCC. Tumours of the lower eyelid, inner canthus, lip, nose, and ear may be amenable to radiotherapy,w37 and it is often used in patients in whom surgery is difficult, inappropriate, or not desired. A recent retrospective analysis of 121 facial BCCs found 90.4% local recurrence-free survival at five years and good cosmetic results.w55
A randomised study of radiotherapy compared with standard excision in the treatment of facial BCC found that radiotherapy had a higher recurrence rate (7.5% v 0.7%) at four years and less acceptable cosmetic outcomes than surgery.w56 w57 Radiotherapy is contraindicated for BCCs that have recurred after previous radiotherapy and in genetic syndromes that predispose to skin cancer. Skin cancers can occur in previous radiotherapy fields. Potential side effects are radionecrosis (especially of the nasal bridge), atrophy, telangiectasia, and damage to the nasolacrimal duct.w58
Photodynamic therapy has become an established treatment for BCC over the past 10 years.w59 w60 Methylaminolaevulinate is the only licensed form of topical photodynamic therapy. This prodrug is preferentially taken up by cancer cells and converted into protoporphyrin IX, a potent photosensitiser. When exposed to visible red light at 630 nm, a photodynamic reaction creates highly active free radicals and singlet oxygen species, which are cytotoxic to cancer cells. This results in selective treatment of the BCC with little reaction on normal surrounding skin. Pain during treatment can be ameliorated with local anaesthetic. Healing can be quick and the cosmetic outcome is often good. In a multicentre randomised study of superficial BCC on the scalp, face, trunk, and extremities, no difference was seen in five year recurrence rates with cryotherapy versus methylaminolaevulinate (20% v 22%). More patients in the photodynamic treatment group than the cryotherapy group reported excellent cosmetic outcome.w61 A prospective randomised multicentre study of nodular BCC found recurrence rates of 14% and 4% at five years for photodynamic treatment and surgery, respectively, but with better cosmesis for photodynamic treatment.w62 Photodynamic treatment has been used for difficult to treat BCCs of the face. One study found a complete response rate of 78% after two years,w63 and a prospective multicentre study found a five year recurrence rate of 38%.w64
Imiquimod is a topical immune response modifier that works by mediating cell death. It is licensed for the treatment of superficial BCCs and should be applied five days a week for six weeks.w65 w66 One study reported no recurrence in 89.5% of 19 low risk facial BCCs treated with imiquimod cream at 39 months of follow-up.w67 Another study looking at imiquimod in 15 patients with periocular BCCs showed 100% clearance at 24 months with favourable cosmetic outcome.w68
Pretreatment patient education, including preprinted leaflets or website recommendations, is needed because of the severe inflammatory reaction.w69 Local skin reactions such as redness, soreness, crusting, and blistering, in addition to flu-like symptoms, have been reported.
Effective treatment depends on tissue penetration. For facial BCC, we use imiquimod for small tumours in low risk areas or patients who will not or cannot be treated with better established treatments with known long term clearance rates.w70
Topical fluorouracil 5% cream works by destabilising DNA. It is sometimes used to treat small superficial BCCs and should be used only at low risk sites. It is therefore not recommended for the treatment of facial BCC.
Curettage and cautery
Curettage involves scraping of the skin; curettage and cautery are sometimes used in low risk BCC but is operator dependent. For benign skin lesions one cycle of curettage is performed, for cancer two to three cycles are needed, but up to a maximum of five cycles may be used.w71 High cure rates can be achieved by experienced staff when tumours are carefully selected.w71 Three cycles of curettage alone in 169 non-aggressive head and neck BCCs achieved a cure rate of 93.5%.w72 Recurrence rates in some studies range from 6% to 19%, and are significantly higher in the central facial areas.w73 Curettage is therefore not generally used for treating facial BCC unless other options are inappropriate.
Cryotherapy is a destructive method of treatment using liquid nitrogen. Operator technique, length of treatment, and number of freeze-thaw cycles vary. Recurrence rates vary from 39% at two years to as low as 1% at five years. w74 w75 Cryotherapy is not recommended as a first line treatment for facial lesions because of high recurrence rates and poor cosmetic outcome.w76
Carbon dioxide and Erb:YAG laser ablation is an uncommon form of treatment, with limited data on its effectiveness. One series showed some benefit in treating small BCCs in low risk sites,w77 but a recent report highlights the dangers of laser treatment on the face. These include a longer disease interval to diagnosis, a more aggressive histological pattern, and the need for more stages of Mohs excision in post-laser BCCs than in primary BCCs.w78
What is the prognosis for facial BCCs?
Most BCC grow slowly, have a non-aggressive course, and can be fairly easily managed. However, long standing or neglected BCCs (fig 5⇓) can present a therapeutic challenge, especially in terms of functional and cosmetic reconstruction. Some may become large or behave like “rodent ulcers,” destroying skin and deeper tissues. Periocular BCC may become inoperable or require exenteration.w79 BCC can occasionally metastasise (0.0028-0.55%).4 w80 w81 For all BCCs, the three year risk of developing a second primary lesion can be as high as 44%.w82 For facial BCC (in one study), up to 39% of patients referred for surgery had multiple primary non-melanoma skin cancer or developed another non-melanoma skin cancer within two years.w83
The overall workload of diagnosis and management is predicted to increase by 50% by 2030,27 and after 2020 the proportion of cases of non-melanoma skin cancer in the over 80 year age group that need treatment will probably rise rapidly worldwide.27 In individual patients, the time to the development of a new lesion decreases with each successive BCC, and this has implications for follow-up.29 The case for follow-up—probably for at least three years—is strongest for patients who have been treated for recurrent disease (increased risk of further recurrence after all types of treatment) and those with a history of multiple BCCs (significantly increased risk of further BCC).19
Tips for non-specialists
Examine the lesion carefully with bright light
Stretch the skin so that the precise extent of tissue involvement can be seen
Use an isopropyl alcohol swab to remove crust or scaling and reveal the underlying lesion. Bleeding often makes diagnosis more straightforward
Palpate the area
Document the size and appearance of the lesion
Additional educational resources
Resources for healthcare professionals
National Institute for Health and Clinical Excellence. NICE guidance on cancer services. improving outcomes for people with skin tumours including melanoma (update): the management of low-risk basal cell carcinomas in the community. 2010. www.nice.org.uk/nicemedia/live/10901/48878/48878.pdf
American Academy of Dermatology (www.aad.org/)—Provides information including clinical guidelines, access to published material, and continuing medical education tools (membership required)
British Association of Dermatologists (www.bad.org.uk//site/622/default.aspx)—Free access to many published guidelines and educational material including lectures
DermNetNZ (http://dermnetnz.org/)—Further resources for medical professionals and a wealth of clinical information
Resources for patients
National Institute for Health and Clinical Excellence. Understanding NICE guidance. Managing low-risk basal cell carcinomas in the community. 2010. www.nice.org.uk/nicemedia/live/10901/48768/48768.pdf. Explains the guidance provided to healthcare professions on deciding which basal cell carcinomas are low risk and whether they can be managed in the community
Cancer Research UK (http://cancerhelp.cancerresearchuk.org//type/skin-cancer/?script=true) —Lots of easy to digest information for the public on the diagnosis and treatment of non-melanoma skin cancer and access to support networks; also has a helpline for patients
British Association of Dermatologists (www.bad.org.uk/site/800/Default.aspx)—Provides downloadable patient leaflets and patient newsletters
Skin Cancer Foundation (www.skincancer.org/skin-cancer-information/basal-cell-carcinoma)—Provides patient information on different types of skin cancer with photographs and warning signs
Macmillan Cancer Support (www.macmillan.org.uk/Cancerinformation/Cancertypes/Skin/Skincancer.aspx)—Lots of information about skin cancer and the various treatments; also has a helpline for patients
A patient’s perspective
I noticed a small red blotch on my forehead but ignored it because I thought it was just a spot. After a few months it was still there so my husband suggested that I get it looked at by my GP.
My GP referred me to a dermatologist who told me he thought it could be a basal cell carcinoma. He arranged for me to have a biopsy to confirm this.
This was something I had never heard of, and I was very worried to know that it was a form of skin cancer. Even though my consultant reassured me that it was not life threatening and would not harm my health I found this news devastating and emotionally distressing. I just wanted to have it removed as soon as possible—it was continually on my mind.
After a wait of a few months I underwent Mohs surgery, which completely removed the lesion. Two months have passed and it has healed with hardly any scarring. I now feel reassured and am ready to put this behind me and get my life back to normal.
Questions for future research
Can subclinical spread of basal cell carcinoma be detected so that surgery plays a more limited role?
Why are increasingly younger people developing basal cell carcinoma?
What is the role of drugs that inhibit the Hedgehog signalling pathway for advanced facial basal cell carcinoma?
Cite this as: BMJ 2012;345:e5342
Thanks to Ian Leach, consultant pathologist, Department of Histopathology, Queen’s Medical Centre.
JMB, AP, and SV wrote the manuscript. SV conceived the idea and design, edited the manuscript, and is guarantor.
Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organisation for the submitted work; SV has received honorariums for educational meetings and invited lectures from Almirall and Leo; SV has advised at a board meeting for Almirall and Roche and received funding to travel to an educational meeting from Leo. JMB and ANP declare no financial relationships with any organisations that might have an interest in the submitted work in the previous three years and no other relationships or activities that could appear to have influenced the submitted work.
Provenance and peer review: Not commissioned; externally peer reviewed.
Patient consent obtained.